A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital)

NCT05098171 | Recruiting Early Phase 1

• 1 other identifier: GC201-2021-10hospital-Gyne
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This study is to investigate the safety and efficacy of signal switch receptor modified TIL (GC201 TIL) in patients with advanced gynecologic tumors. Autologous TILs from tumor resections or biopsies are first gene modified(TGF-β receptor or PD-1 gene modified TILs which could transfer the suppression signal surrounding the microenvironment of tumor bed into persistent T cell activation signal) and than expanded before i.v. infusion into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Conditions

Advanced Gynecologic Tumors; Signal Switch Receptor Modified TIL; Treatment Side Effects; Effects of Immunotherapy

Outcome Measures

Primary Outcomes (6)

• Adverse Events (AE)

  To characterize the safety profile of Signal Switch Receptor Modified TIL (GC201 TIL) in patients with advanced gynecologic tumors as assessed by incidence of adverse events related to GC201 TIL infusion.

  Up to 6 months

• Objective Response Rate (ORR)

  Proportion of patients with response per Response Evaluation Criteria in Solid Tumors (RECIST v1.1): ORR (proportion of patients) = # with CR + # with PR / # with CR + # with PR + # with SD + # with PD. ( Except baseline evaluation within 28 days before TIL infusion，PET/CT scan will be performed at 6 weeks after GC201 TIL infusion, and than every 6 weeks for 6 months, and then every 6 months after that for up to 3 years)

  Up to 36 months

• Disease Control Rate (DCR）

  Percentage of patients that meet CR, PR and SD criteria set in this study according to RECIST v1.1： DCR (proportion of patients) = # with CR + # with PR + # with SD / # with CR + # with PR + # with SD + # with PD.

  Up to 36 months

• Duration of Response (DOR)

  The time length between the first confirmed objective response per RECIST 1.1 to the treatment and the subsequent disease progression per RECIST 1.1

  Up to 36 months ]

• Progression-Free Survival (PFS)

  The time length between GC201 TIL infusion and confirmed subsequent disease progression according to RECIST 1.1

  Up to 36 months

• Overall Survival (OS)

  The length of time from the date of the start of GC201 TIL treatment that the patients are still alive

  Up to 36 months ]

Secondary Outcomes (1)

• Change in Quality of Life

  Up to 36 months

Study Arms (1)

Signal Switch Receptor Modified TIL

EXPERIMENTAL

2x10\^8-1x10\^10 in vitro expanded autologous PD-1 or TGF-β signal switch receptor modified TIL (GC201 TIL) will be infused i.v. to patients with advanced gynecologic tumors after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Biological: Signal Switch Receptor Modified TIL

Interventions

Signal Switch Receptor Modified TIL BIOLOGICAL

Adoptive transfer of 2x10\^8-1x10\^10 autologous signal switch receptor modified TILs to patients i.v. in 30-120 minutes.

Signal Switch Receptor Modified TIL

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age: 18 years to 75 years;
• Histologically diagnosed as primary/relapsed/metastasized Gynecological tumors;
• Expected life-span more than 3 months;
• Karnofsky≥60% or ECOG score 0-2;
• Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available.
• Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated;
• At least 1 evaluable tumor lesion;
• Hematology and Chemistry（within 7 days prior to enrollment）:
• Absolute count of white blood cells≥2.5×10\^9/L;
• Absolute count of neutropils≥1.5×10\^9/L;
• Absolute count of lymphocytes ≥0.7×109/L；
• Platelet count≥100×10\^9；
• hemoglobin≥90 g/L;
• Activated partial thromboplastin time (APTT) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days);
• International normalized ratio (INR) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days);

You may not qualify if:

• Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment;
• Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40%;
• Significant cardiovascular anomalies according to any of the following definition: New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrio-ventricular conductive block, etc.
• Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and/or anti-HCV positive), syphilis infection or Treponema pallidum antibody positive;
• Severe physical or mental diseases;
• Have a systemic active infection requiring treatment, or have positive blood cultures(or imaging evidence of infection);
• Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy;
• History of allergy to chemical compound consisting of chemical and biologic substances resembling cell therapy;
• Having received immunotherapy and developed irAE level greater than Level 3;
• Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded);
• Females in pregnancy or lactation;
• History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy;
• Researchers considering the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study.

Sponsors & Collaborators

• Shanghai 10th People's Hospital: collaborator
• Shanghai Juncell Therapeutics: lead

Study Sites (1)

Shanghai Tenth People's Hospital

Shanghai, Shanghai Municipality, 200000, China

RECRUITING

Central Study Contacts

Clinical GC

CONTACT

086-18001759113; clinicaltrials@juncell.com

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 12, 2021
• First Posted: October 28, 2021
• Study Start: September 26, 2021
• Primary Completion (Estimated): September 25, 2026
• Study Completion (Estimated): September 25, 2027
• Last Updated: December 11, 2025

Record last verified: 2025-12

Locations

CN (1)